Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy

Journal of Medical Economics

Volumn 18, Issue 9, 2015, Pages 678-690

  Cure, Sandrine ^a   Guerra, Ines ^a   Cammà, Calogero ^b   Craxì, Antonio ^b   Carosi, Giampiero ^c  

^a Mapi   (United Kingdom)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Boceprevir; Chronic hepatitis C infection; Cost effectiveness analysis; Italy; Sofosbuvir; Telaprevir

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE;

AGED; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HIDDEN MARKOV MODEL; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH SERVICE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; ECONOMICS; GENOTYPE; HEPATITIS C, CHRONIC; MARKOV CHAIN; PATIENT ATTITUDE; QUALITY ADJUSTED LIFE YEAR; SEVERITY OF ILLNESS INDEX;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; ITALY; MARKOV CHAINS; PATIENT ACCEPTANCE OF HEALTH CARE; POLYETHYLENE GLYCOLS; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; SOFOSBUVIR;

EID: 84940370117     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1040024     Document Type: Article

References (44)

1. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52
2. Torre GL, Gualano MR, Semyonov L et al. Hepatitis C virus infections trends in Italy, 1996-2006. Hepat Mon 2011;11:895-900
3. Cornberg M, Razavi HA, Alberti A et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International 2011;31:30-60
4. Ciampichini R, Scalone L, Fagiuoli S, et al. Societal burden in hepatitis C patients: the come study results. Value in Health Conference: 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR, 2 June 2012, Washington, DC, USA
5. Mennini FS. Il costo dell'epatite C. WEF, 2012. Facoltá di Economia, Universitá di Roma Tor Vergata and Kingston Business School, Kingston University, London, UK
6. EASL (European Association for the Study of the Liver). EASL Recommendations on Treatment of Hepatitis C. 2014. http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf [last accessed 30 January 2015]
7. Therapy KnowlEdge HCV di Edge Consulting srl., 2014
8. North CS, Hong BA, Adewuyi SA, et al. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry 2013;35:122-8
9. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-92
10. Belperio PS, Hwang EW, Thomas IC, et al. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C. Clin Gastroenterol Hepatol 2013;11:1021-7
11. Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2013;22:1107-21
12. EMA. Sovaldi Summary of Product Characteristics (SmPC). 2014. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002798/WC500160597.pdf [last accessed 30 January 2015]
13. EASL. Clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420
14. Shepherd J, Jones J, Hartwell D et al. Interferon alfa (pegylated and nonpegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-224
15. Hartwell D, Jones J, Baxter L, et al. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011;15:i-210
16. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-5
17. Fattore G. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. Pharmacoeconomics Ital Res Articles 2009;11:83-93
18. Craxi A, Piccinino F, Ciancio A, et al. Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study. Eur J Gastroenterol Hepatol 2014;26:388-95
19. McLauchlan J. Query of 5000 anonymised patient records performed October 2013. HCV UK Research Database, 2013
20. Associazione italiana per lo studio del fegato. 2011. Available at: http://www.webaisf.org/[last accessed 30 January 2015]
21. Bacon B, Dieterich D, Flamm S, et al. Efficacy of sofosbuvir and simeprevirbased regimens for HCV treatment-experienced GT1 patients in a real-life setting; data from the TRIO network. 65th Annual Meeting of the American Association for the Study of Liver Diseases, 7 November 2014, Boston, MA, USA
22. EMA. Incivo Summary of Product Characteristics (SmPC). 2014. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002313/WC500115529.pdf [last accessed 30 January 2015]
23. EMA. Victrelis Summary of Product Characteristics (SmPC). 2014. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002332/WC500109786.pdf [last accessed 30 January 2015]
24. Grishchenko M, Grieve RD, Sweeting MJ, et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009;25:171-80
25. Istituto nazionale di statistica. 2012. Available at: http://www.istat.it/it/istituto-nazionale-di-statistica [last accessed 30 January 2015]
26. Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10:1-113,iii
27. Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014;60:741-7
28. National Institute for Health and Clinical Excellence. Telaprevir for the treatment of genotype 1 chronic hepatitis C-NICE technology appraisal guidance 252. 2012. http://www.google.com/url?url=http://www.nice.org. uk/guidance/ta252/resources/guidance-telaprevir-for-the-treatment-of-genotype-1-chronic-hepatitis-c-pdf&rct=j&frm=1&q=&esrc=s&sa=U&ei=gtg0 VbGEEJGxogSA8oGoCg&ved=0CBQQFjAA&usg=AFQjCNGNJVJwQ8Vpskiux-Emm8Lx9-YHWA [last accessed 30 January 2015]
29. National Institute for Health and Clinical Excellence. Boceprevir for the treatment of genotype 1 chronic hepatitis C-NICE technology appraisal guidance 253. 2012. https://www.google.com/url?url=https://www.nice.org.uk/guidance/ta253/resources/guidance-boceprevir-for-the-treatment-of-genotype1-chronic-hepatitisc-pdf&rct=j&frm=1&q=&esrc=s&sa=U&ei=udg0 VYXZMoG3ogSS-YCoCQ&ved=0CBQQFjAA&usg=AFQjCNGFzlFb8l-IvkzCp DcKtd-2oAL2IQ [last accessed 30 January 2015]
30. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92
31. Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making 2006;26:18-29
32. Remunerazione delle prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. Supplemento ordinario alla 'Gazzetta Ufficiale' n. 23 del 28 gennaio 2013-Serie generale. DM, 2012. http://www.gazzettaufficiale.it/eli/id/2013/01/28/13A00528/sg
33. Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014;59:1692-705
34. Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat 2015;22:376-83
35. Deuffic-Burban S, Schwarzinger M, Obach D, et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). J Hepatol 2014;61:7-14
36. San MR, Gimeno-Ballester V, Blazquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 2014. pii: gutjnl-2014-307772. doi: 10.1136/gutjnl-2014-307772. [Epub ahead of print]
37. Saab S, Gordon SC, Park H, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014;40:657-75
38. Lawitz E, Zeuzem S, Nyberg L, et al. Boceprevir (BOC) Combined with Peginterferon alfa-2b/Ribavirin (P/RBV) in Treatment-Naïve Chronic HCV Genotype 1 Patients with Compensated Cirrhosis: Sustained Virologic Response (SVR) and Safety Subanalyses from the Anemia Management Study, Abstract 50. Boston, MA: AASLD, 9-12 November 2012
39. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
40. Lagging M, Rembeck K, Rauning BM, et al. Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Scand J Gastroenterol 2013;48:839-47
41. Shoeb D, Rowe IA, Freshwater D, et al. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse. Eur J Gastroenterol Hepatol 2011;23:747-53
42. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
43. Thomson BJ, Kwong G, Ratib S, et al. Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management. J Viral Hepat 2008; 15:271-8
44. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72